Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thrombomodulin alfa - Asahi Kasei Pharma Corp

Drug Profile

Thrombomodulin alfa - Asahi Kasei Pharma Corp

Alternative Names: ART-123; AT 908; Human recombinant thrombomodulin - Asahi Kasei Pharma Corp; Recombinant human soluble thrombomodulin - Asahi Kasei Pharma Corp; Recombinant thrombomodulin alfa - Asahi Kasei Pharma Corp; Recombinant thrombomodulin alpha - Asahi Kasei Pharma Corp; Recomodulin; Recomodulin® anticoagulant intravenous infusion 12800; rhs-TM - Asahi Kasei Pharma Corp; Thrombomodulin alpha - Asahi Kasei Pharma Corp; TMD-123

Latest Information Update: 17 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asahi Kasei; Asahi Kasei Pharma Corp
  • Developer Asahi Kasei; Asahi Kasei Pharma America Corp; Asahi Kasei Pharma Corp
  • Class Anti-inflammatories; Anticoagulants; Antifibrotics; Antithrombotics; Peptides; Platelet membrane glycoproteins; Recombinant proteins
  • Mechanism of Action Protein C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Disseminated intravascular coagulation
  • Phase II Peripheral nervous system diseases
  • Discontinued Deep vein thrombosis; Idiopathic pulmonary fibrosis

Most Recent Events

  • 16 Mar 2021 Phase III development is ongoing in Disseminated intravascular coagulation in sepsis (severe sepsis with coagulopathy) outside Japan (IV) (Asahi Kasei Pharma Corp website, March 2021)
  • 16 Mar 2021 Phase-II clinical development is ongoing in Peripheral nervous system diseases (Chemotherapy-induced) in Japan (IV) (Asahi Kasei Pharma Corp pipeline, March 2021)
  • 31 Jul 2020 Asahi Kasei Pharma America Corporation plans a phase II trial for Peripheral neuropathies (chemotherapy induced) in November 2020 (NCT04492436)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top